Amendments for: 172-2021-2022-Q4-971509

Current (Jan 14, 2022)
Agreement Value: $259,257.00
Agreement: Analytical validation and translation of COVID detection and patient stratification technologies for Critical Care (971509). Apr 14, 2021 - Mar 31, 2022
Description:

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), is commonly diagnosed by reverse transcription polymerase chain reaction (RT-PCR) to detect viral RNA in patient samples. While pathogen diagnosis is critical, patient outcomes vary depending upon the host’s immune response to the virus. Currently, there are no tests that inform - at the point-of-need - how to risk stratify patients once they test positive for SARS-CoV2. Identifying subgroups of COVID patients that are more likely to require specific therapies, tertiary level care or who are safe to be discharged home with minimal monitoring will significantly improve the ability to plan and prepare while preserving resources when individuals are unlikely to have severe disease. Currently, there are no methods to differentiate early-on an individual who will remain asymptomatic from one who will require advanced treatments.
Using genomic precision medicine technology, the PRecision mEDIcine for CriTical Care (PREDICT), The Recipient with their collaborators identified an 8-gene expression signature that has the potential to identify COVID patients at risk for significant morbidity and mortality. Early diagnosis combined with determination of categories of risk should aid significantly in therapeutic treatment of COVID patients and preparedness for future pandemics. In this Project, the Recipient aims to determine if the 8-gene expression signature can be set-up on the PowerBlade Droplet Digital PCR (ddPCR) platform with the view to establishing fast and accurate detection of patient-precision marks in a critical care setting.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: Unity Health Toronto (Academia)
Location: Toronto, Ontario, CA M5B 1W8
Type: Grant
Additional Information:

This agreement has been amended 1 time(s). The total amended value is 259,257 dollars and the end date of this agreements has been modified by 159 days.

Federal Riding Name: Toronto Centre (35108)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710